Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 72 of 475 for:    CANDOX OR CAREXIL OR OXYCONTIN OR OXYNORM OR RELTEBON OR LEVERAXO OR LONGTEC OR OXAYDO OR SHORTEC OR OXELTRA OR OXYLAN OR ZOMESTINE OR OXYCODONE HYDROCHLORIDE OR ROXYBOND OR ROXICODONE OR LYNLOR OR OXECTA OR ABTARD OR DOLOCODON PR

A Study to Evaluate Safety and Efficacy Following Dosing of Oxycodone/Naltrexone for Treatment of Adults With Pain Following Bunionectomy Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02401750
Recruitment Status : Completed
First Posted : March 30, 2015
Last Update Posted : August 9, 2016
Sponsor:
Information provided by (Responsible Party):
Elite Laboratories, Inc

Brief Summary:
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, Phase 3 study to evaluate the efficacy and safety of the administration of multiple doses of Oxycodone Hydrochloride plus Naltrexone Hydrochloride (a) or Oxycodone Hydrochloride plus Naltrexone Hydrochloride (b) in patients who have undergone primary, unilateral, distal first metatarsal bunionectomy with osteotomy and internal fixation.

Condition or disease Intervention/treatment Phase
Pain Drug: Oxycodone Naltrexone (a) Drug: Oxycodone Naltrexone (b) Drug: Placebo Phase 3

Detailed Description:
The study is designed to evaluate the safety and efficacy of oxycodone/naltrexone (a) and oxycodone/naltrexone (b) versus placebo. During the blinded phase of the study (inpatient portion) the dosing regimen is 1 capsule containing Oxycodone Hydrochloride plus Naltrexone Hydrochloride (a) or Oxycodone plus Naltrexone Hydrochloride (b) or placebo taken with 4 to 6 ounces (oz) of water every 6 hours (q6h) for 48 hours following the first dose (Multiple-dose Period) while in-house. Then for the open-label phase of the study (outpatient portion) dosing will occur every 4 to 6 hours prn with Oxycodone plus naltrexone. The active and placebo study medications will appear identical. Study subjects with acute postoperative pain of moderate to severe intensity following unilateral bunionectomy surgery will be randomized after surgery, and will stay at the study center for the duration of the 48-hour double-blind period after dose 1 of study medication. The study will be conducted in the following 4 periods: 1) a pre-treatment period, 2) a multiple-dose inpatient period (double-blind), 3) a multiple-dose outpatient period (open-label), and 4) End of Study/Follow-up.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 163 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multi-center, Randomized, Multiple-dose, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Abuse-deterrent Capsules Oxycodone Hydrochloride Plus Naltrexone Hydrochloride (a) or Oxycodone Hydrochloride Plus Naltrexone Hydrochloride (b) for the Treatment of Adults With Moderate to Severe Pain Following Bunionectomy Surgery
Study Start Date : June 2015
Actual Primary Completion Date : July 2015
Actual Study Completion Date : September 2015

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Oxycodone Naltrexone (a)
Double-Blind Oxycodone/Naltrexone, 1 capsule by mouth every 6 hours for 48 hours
Drug: Oxycodone Naltrexone (a)
Experimental: Oxycodone Naltrexone (b)
Double-Blind Oxycodone/Naltrexone , 1 capsule by mouth every 6 hours for 48 hours
Drug: Oxycodone Naltrexone (b)
Placebo Comparator: Placebo
Double-Blind Placebo to experimental Oxycodone/Naltrexone, 1 capsule every 6 hours for 48 hours
Drug: Placebo
Matches both experimental drugs




Primary Outcome Measures :
  1. Pain Intensity Measure for Oxycodone/Naltrexone (a) [ Time Frame: Every 6 hours for 48 hours ]
    Self reported pain intensity prior to 1st dose, every 30 minutes for the 1st 6 hours, immediately prior to each drug administration (every 6 hours) and at 2 hours after each drug administration. Each is scored 0-10 (0=no pain and 10 = worst pain imaginable) on a Likert Scale


Secondary Outcome Measures :
  1. Pain Intensity Measure for Oxycodone/Naltrexone (b) [ Time Frame: Every 6 hours for 48 hours ]
    Self reported pain intensity prior to 1st dose, every 30 minutes for the 1st 6 hours, immediately prior to each drug administration (every 6 hours) and at 2 hours after each drug administration. Each is scored 0-10 (0=no pain and 10 = worst pain imaginable) on a Likert Scale

  2. Pain Relief Measure for Oxycodone/Naltrexone (a and b formulations) [ Time Frame: Every 6 hours for 48 hours ]
    Self reported pain relief, every 30 minutes for the 1st 6 hours, immediately prior to each drug administration (every 6 hours) and at 2 hours after each drug administration. Pain relief is scored on a 5 point scale of None, A Little, Some, A Lot and Complete Relief from the starting pain.

  3. Number of Subjects with Changes in Physical Examination from Day 1 Pre-dose to End of Study [ Time Frame: Pre-Dose Day 1 and Day 8 ]
    Changes in Physical Exam will be evaluated/analyzed from Day 1 Pre-dose to Day 8. Descriptive statistics will be used (number and percent of occurrences).

  4. Number of Subjects with Changes in Pulse Oximetry from Pre-Dose to post-dose time points [ Time Frame: 48 hours (multiple time points) and at each out patient visit (Days 4, 6, 8) ]
    Changes in Pulse Oximetry will be evaluated/analyzed from pre-dose to post-dose values. Descriptive statistics will be used (number and present of occurrences).

  5. Number of Subjects with Changes in Blood Chemistry Analytes from baseline to end of study [ Time Frame: Screening, 48 hours post-dose and Day 8 ]
    Changes in Blood Chemistry values at 48 hours post-dose and end of study will be evaluated/analyzed from baseline (screening) values. Descriptive statistics will be used (number and percent of occurrences).

  6. Number of Subjects with Changes in Hematology Analytes from baseline to end of study [ Time Frame: Screening, 48 hours post-dose and Day 8 ]
    Changes in Hematology values at 48 hours post-dose and end of study will be evaluated/analyzed. Descriptive statistics will be used (number and percent of occurrences).

  7. Number of Subjects with Changes in Urinalysis from baseline to end of study [ Time Frame: Screening, 48 hours post-dose and Day 8 ]
    Changes in Urinalysis at 48 hours post-dose and end of study will be evaluated/analyzed. Descriptive statistics will be used (number and percent of occurrences)

  8. Number of Subjects with Changes in Systolic Blood Pressure from baseline through multiple post-dose time points [ Time Frame: Pre-Dose Day 1 through Day 3, Day 4, 6, 8 ]
    Blood pressure will be done every 6 hours for the 1st 48 hours then at each outpatient visit. Descriptive statistics will be used (number and percent of occurrences) of changes from baseline to subsequent time points post-dose.

  9. Number of Subjects with Changes in Diastolic Blood Pressure from Baseline through multiple time points post-dose [ Time Frame: Pre-Dose Day 1 through Day 3, Day 4, 6, 8 ]
    Blood pressure will be done every 6 hours for the 1st 48 hours then at each outpatient visit. Descriptive statistics will be used (number and percent of occurrences) of changes from baseline to subsequent time points post-dose.

  10. Number of Subjects with Changes in Pulse Rate [ Time Frame: Pre-Dose Day 1 through Day 3, Day 4, 6, 8 ]
    Pulse rate will be measured every 6 hours for the 1st 48 hours then at each outpatient visit. Descriptive statistics will be used (number and percent of occurrences) of changes from baseline to subsequent time points post-dose.

  11. Number of Subjects with Changes in Respiratory Rate [ Time Frame: Pre-Dose Day 1 through Day 3, Day 4, 6, 8 ]
    Respiratory rate will be measured every 6 hours for the 1st 48 hours then at each outpatient visit. Descriptive statistics will be used (number and percent of occurrences) of changes from baseline to subsequent time points post-dose.

  12. Number of subjects with Adverse Events as a measure of Safety and Tolerability [ Time Frame: Day 1 through 7 days post last dose ]
    Number of subjects that reported an Adverse Event will be reported by body system, severity, relatedness to study drug as number and percent of occurrences.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Complete the informed consent process as documented by a signed informed consent form (ICF).
  2. Be in generally good health and classified as either PS-1 or PS-2 by the American Society of Anesthetists (ASA) Physical Status Classification System.
  3. Be male or female, age 18 to 75 years, inclusively at the time of screening.
  4. Be scheduled for a primary, unilateral, distal, first metatarsal bunionectomy with osteotomy and internal fixation (with no collateral procedures)
  5. Female subjects are eligible only if all of the following apply:

    • Not pregnant (subjects of child-bearing potential must have a negative serum beta-human chorionic gonadotropin (B-hCG) pregnancy test at screening and a negative urine pregnancy test before surgery);
    • Not lactating;
    • Not planning to become pregnant within the duration of study;
    • Surgically sterile (bilateral tubal ligation or hysterectomy), or at least two years postmenopausal, or is practicing an acceptable form of birth control (defined as the use of an intrauterine device [IUD], a barrier method with spermicide, condoms, any form of hormonal contraceptives, partner with a vasectomy (surgery at least 6 weeks prior to start of surgery) or abstinence ) for at least 3 months prior to the screening visit and agrees to continue acceptable methods of contraception until one week following the last dose of ELI-200.
  6. Be willing to complete the pain assessments and return to clinic as scheduled.
  7. Subjects must experience postoperative pain (Day 1) that is at least moderate as measured by a NRS score ≥ 4 on a 0-10 NRS, less than 9 hours after discontinuing the nerve block.

Exclusion Criteria:

  1. Have an uncontrolled medical condition, serious intercurrent illness, clinically significant general health condition, or extenuating circumstance that may significantly decrease study compliance or otherwise preclude their participation in the study.
  2. Have a clinically significant abnormal electrocardiogram (ECG) at screening as determined by the Investigator.
  3. Have had any type of gastric bypass surgery or have a gastric band. Have previous abdominal surgery within the past year or history of abdominal adhesions, known or suspected paralytic ileus.
  4. Have a history of any medical condition or surgical procedure that would alter the absorption, distribution, metabolism or excretion of oxycodone or any opioid including but not limited to severe chronic diarrhea, chronic constipation, irritable bowel syndrome, or bowel resection.
  5. Have a history of severe bronchial asthma, hypercarbia, or hypoxia (oxygen partial pressure [PO2] <92%) or any respiratory condition that, in the opinion of the investigator, makes the subject unsuitable for the study. Mild episodic asthma or exercised induced asthma will be allowed.
  6. Have, in the opinion of the investigator, a clinically significant abnormality on their clinical laboratory values (urinalysis, hematology and chemistry) at screening.
  7. Have glycosylated hemoglobin (2c) > 7%.
  8. Have Addison's disease, benign prostatic hyperplasia, or kidney disease or other conditions as outlined in the Investigator's Brochure or the Percocet and Oxycontin Package Inserts that are contraindicated for use.
  9. Have made a donation (standard donation amount or more) of blood or blood products (with the exception of plasma as noted below) within 56 days prior to Day -1 .
  10. Have made a plasma donation within 7 days prior to Day -1.
  11. Have a known allergy or hypersensitivity to any opioid analgesics, naltrexone, anesthetics (eg, propofol), acetaminophen, NSAIDs (eg, ibuprofen or naproxen, ketorolac) or any of the excipients
  12. Have a known allergy or hypersensitivity to ropivacaine, Mepivacaine, Lidocaine or any related drug.
  13. Have a history of significant intolerance (in the opinion of the investigator) or allergic hypersensitivity reaction to opioid use.
  14. Not be willing to discontinue the prohibited medications, within the allotted time before surgery and throughout the duration of their participation in the study.
  15. Have a history of substance(more than recreational use) or alcohol (more than 14 drinks in a week) abuse within 2 years before screening.
  16. Have a positive drug screen or alcohol screen result.
  17. Use of anti-coagulant agents (eg, Coumadin, heparin, etc)
  18. Have a positive test for human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) at the screening visit.
  19. Have an active malignancy of any type, or has been diagnosed with cancer within 5 years prior to screening (excluding squamous or basal cell carcinoma of the skin).
  20. Have dysphagia and/or cannot swallow study medication whole.
  21. Use concurrent therapy that could interfere with the evaluation of efficacy or safety parameters in the opinion of the investigator. (eg, any drugs, in the investigators opinion, that may exert significant analgesic properties or act synergistically with oxycodone, morphine, ketorolac, acetaminophen or ibuprofen).
  22. Have a history of seizures or history of serious head injury.
  23. Must not be a member of a vulnerable population as defined by the Code of Federal Regulations Title 45, Part 46, Section 46.111(b), including but not limited to employees (temporary, part-time, full-time, etc.) or a family member of the research staff conducting the study, or of the Sponsor, or of the Clinical Research Organization.
  24. Have previously participated in a clinical trial using (Oxycodone Hydrochloride Naltrexone Hydrochloride, 1.5 mg or Oxycodone Hydrochloride , Naltrexone Hydrochloride 3.0 mg ).
  25. Have a history of major mental illness that in the opinion of the Investigator may affect the ability of the subject to participate in the study. Institutionalized subjects will not be eligible for participation.
  26. Been exposed to any investigational agent within 30 days or five half-lives (whichever is longer) prior to check-in for Day 1, Period 1, or is scheduled to receive an investigational device or drug (other than test product) during the course of this study.

Day -1 Exclusions:

1. Have taken any of the following drugs within the indicated times before surgery:

  • over-the-counter or prescription non-steroidal anti-inflammatory drugs (NSAIDs) (such as ibuprofen [Advil®, Motrin®]), acetaminophen, or naproxen sodium (Anaprox®, Aleve®) within 24 hours; a daily dose of 81 mg of aspirin will be allowed (higher doses must be lowered to 81 mg a day by 72 hours prior to surgery).
  • naproxen sodium sustained-release (Naprelan®) within 72 hours
  • C-2 inhibitors (such as piroxicam or indomethacin) within 5 days
  • oxycodone-containing drugs and other analgesic drugs containing opioids within the past 14 days
  • immediate-release sedating antihistamines, tranquilizers, or hypnotics within at least 6 hours, or long-acting or sustained-released forms of these drugs within at least 7 days of Day -1

Day 1 Exclusion:

1. Have surgical complications (Day -1) that could compromise the safety of the subject or confound the results of the trial or any other reason that, in the opinion of the investigator, makes the subject unsuitable to participate.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02401750


Locations
Layout table for location information
United States, Arizona
Premier Research
Phoenix, Arizona, United States, 85027
United States, Maryland
Chesapeake Research Group
Pasadena, Maryland, United States, 21122
United States, Texas
Premier Research
Austin, Texas, United States, 78705
Endeavor Clinial Trials
San Antonio, Texas, United States, 78240
United States, Utah
Jean Brown Research
Salt Lake City, Utah, United States, 84124
Sponsors and Collaborators
Elite Laboratories, Inc

Layout table for additonal information
Responsible Party: Elite Laboratories, Inc
ClinicalTrials.gov Identifier: NCT02401750     History of Changes
Other Study ID Numbers: ELI-003-2014
First Posted: March 30, 2015    Key Record Dates
Last Update Posted: August 9, 2016
Last Verified: August 2016

Additional relevant MeSH terms:
Layout table for MeSH terms
Oxycodone
Naltrexone
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Alcohol Deterrents
Narcotic Antagonists